Returning to Barcelona in September 2026, Advanced Therapies Europe will bring together global healthcare leaders to address the challenges shaping the future of cell, gene and regenerative medicine.
The future of healthcare is increasingly being shaped by advanced therapies, with cell, gene and regenerative medicine opening new possibilities for treating complex conditions. Yet as scientific breakthroughs continue to accelerate, the industry faces a new set of challenges around regulation, investment, manufacturing scale-up and commercialisation.
Against this backdrop, Advanced Therapies Europe 2026 will return to Barcelona from 7–9 September, bringing together the leaders, innovators and decision-makers responsible for driving the next phase of progress across the advanced therapies ecosystem. The event will take place at the InterContinental Barcelona and is designed to connect organisations working across the full journey, from early-stage science through to commercial delivery.
Organised by Phacilitate Advanced Therapies Europe 2026, the event will provide a dedicated platform for biotech executives, pharmaceutical leaders, investors, academics, regulators and solution providers to exchange insights, develop partnerships and explore the opportunities shaping the future of advanced medicine.
As the sector moves beyond scientific discovery and towards wider patient access, collaboration across disciplines is becoming increasingly important. Developers must navigate complex regulatory pathways, establish scalable manufacturing processes, secure investment and create sustainable commercial strategies – all while ensuring that transformative therapies reach the patients who need them.
Advanced Therapies Europe 2026 has been designed around these industry priorities, creating opportunities for senior stakeholders to engage in meaningful discussions and develop practical solutions to shared challenges.
One of the defining challenges facing the advanced therapies industry is the transition from successful research and clinical development into reliable commercial delivery.
For cell and gene therapies in particular, manufacturing capacity, operational efficiency and supply chain resilience remain critical considerations. Organisations must balance the complexity of producing highly personalised treatments with the need to create repeatable processes capable of supporting broader adoption.
Alongside manufacturing, the sector continues to navigate evolving regulatory environments and shifting investment landscapes. Advanced Therapies Europe will provide a forum for stakeholders to examine these pressures while exploring strategies for sustainable growth across Europe’s life sciences ecosystem.
Beyond its conference programme, Advanced Therapies Europe places a strong emphasis on collaboration and targeted networking. The event’s format is designed to encourage direct engagement between organisations looking to invest, partner, scale operations or bring new therapies to market.
Previous editions have highlighted the value of bringing together decision-makers from across biotech, pharma, investment, manufacturing and healthcare. For 2026, the event will continue this approach by creating a focused environment where attendees can build relationships, share expertise and identify opportunities for collaboration.
The event will also feature dedicated areas focused on investment, innovation and specialist communities, reflecting the diverse range of stakeholders involved in advancing next-generation therapies.
As Europe’s advanced therapies landscape continues to evolve, the need for collaboration between scientific innovators, industry leaders and healthcare stakeholders has never been greater.
Advanced Therapies Europe 2026 will provide a meeting point for those working to overcome the practical challenges of bringing breakthrough therapies from concept to patient impact. By connecting expertise across research, development, manufacturing, investment and commercialisation, the event aims to support the partnerships needed to move the industry forward.
EME Outlook readers can access an exclusive 20 percent discount on tickets using the code HEALTHOUT20.
